- Home
- ESLA vs LSTA Comparison
ESLA vs LSTA Comparison
Compare ESLA & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | LSTA |
|---|---|---|
| Founded | 2021 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 28.9M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | ESLA | LSTA |
|---|---|---|
| Price | $0.75 | $1.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $8.00 | ★ $15.00 |
| AVG Volume (30 Days) | 34.6K | ★ 119.6K |
| Earning Date | 05-26-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.68 | $0.99 |
| 52 Week High | $3.15 | $5.07 |
Technical Indicators
Market Signals| Indicator | ESLA | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 37.45 | 19.70 |
| Support Level | N/A | N/A |
| Resistance Level | $1.35 | $2.19 |
| Average True Range (ATR) | 0.07 | 0.22 |
| MACD | 0.00 | -0.12 |
| Stochastic Oscillator | 19.82 | 4.16 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.